Investigation Launched into Kezar's Transaction with Aurinia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Source: Globenewswire
- Shareholder Rights Investigation: Ademi LLP is investigating Kezar (NASDAQ: KZR) for potential breaches of fiduciary duty in its transaction with Aurinia, aiming to ensure the protection of all shareholders' rights.
- Cash and Rights Compensation: In this transaction, Kezar shareholders will receive $6.955 in cash per share plus a contingent value right (CVR), which involves potential payments from the clinical development of zetomipzomib and proceeds from collaboration with Everest Medicines, highlighting the complexity and potential value of the deal.
- Internal Conflicts of Interest: Kezar insiders will receive substantial benefits as part of change of control arrangements, raising concerns about whether the board is fulfilling its fiduciary duties to all shareholders, which could impact corporate governance.
- Restrictions on Competing Transactions: The transaction agreement imposes significant penalties on Kezar for accepting competing bids, potentially harming shareholder interests and necessitating further legal scrutiny of the deal.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
